Colin Hislop, MD
As SVP Clinical Development, Dr. Colin Hislop leads Juvena’s clinical-stage drug candidates. His 36-year tenure in drug development and life sciences spans multinational roles across therapeutic areas at companies including Lilly (formerly Eli Lilly & Company), Proctor & Gamble Pharmaceuticals, Peninsula Therapeutics, Versartis Inc. Anthera Pharmaceuticals and most recently Eiger BioPharnaceuticals. His expertise encompasses early and late-stage clinical development as well as the successful prosecution of multiple drug approvals.
Just prior to Juvena, Dr. Hislop helped lead the successful prosecution of an NDA (2020) and MAA (2022) for lonafarnib to treat an ultra-rare genetic disease called Hutchinson-Guilford Progeria Syndrome. Other roles include Chief Medical Officer at Versartis Inc.; SVP and Chief Medical Officer at Anthera Pharmaceuticals where he served on the leadership team to take the Company public.
Dr. Hislop obtained an undergraduate degree in Medical Biochemistry from the University of Surrey and his medical degree from the Middlesex Hospital Medical School, University of London.
Learn more about Dr. Colin Hislop
